For laboratory research use only. Not for human or veterinary use.Lab research use only. Not for human or animal use.
Cart is empty
Same-Day DispatchAustralian StockPremium Research GradePublished CoAsPayID · Clears in SecondsSame-Day DispatchAustralian StockPremium Research GradePublished CoAsPayID · Clears in Seconds
Same-day dispatch on business-day orders before 12pm Sydney time.Same-day dispatch before 12pm Sydney timeFree standard post $199+Free std post $199+
Tirzepatide 40 mg is a research-grade peptide that binds both the GIP and GLP-1 receptors, supplied in Australia by Australian Research Peptides to laboratories and researchers. It is the largest of three strengths ARP lists. The 40 mg vial is independently lab-tested; no certificate is published for it yet. Tirzepatide (tirz) is a laboratory-made chain of 39 amino acids modelled on GIP, a hormone the gut releases. This 40 mg vial costs A$269.99 and is out of stock today; ARP ships from within Australia to all states and territories. For in vitro research purposes only.
Tirzepatide 40 mg is sold out for now. Leave your email and ARP will send you one email the day it is back. Nothing else.
Presentation
40 mg per vial
Grade
Research Grade
Form
Lyophilised Powder
Category
Metabolic Research
This strength is not in stock — stocked lines dispatch same business day before 12pm Sydney time, Mon–Fri
Tracked shipping Australia-wide · typically 1–2 business days to most areas by Express Post · free post over $199, free Express over $299
For in vitro research purposes only. Not for human consumption. Not for animal consumption. This product is not a drug, food, cosmetic, or dietary supplement. No medical, therapeutic, or usage information is provided.
Tirzepatide's single engineered chain reaches two receptor targets, GIP and GLP-1, where semaglutide reaches only GLP-1 and retatrutide adds glucagon. This is the 40 mg Tirzepatide vial, the largest of three, listed as 47263.
Nothing is published for the 40 mg size yet — Tirzepatide lots are independently lab-tested, and the certificate follows.
In vitro GIP and GLP-1 receptor research purposes only. Australian Research Peptides does not supply Tirzepatide for human or veterinary use.
Tirzepatide is a laboratory-made peptide studied in metabolic research that binds two hormone receptors, GIP and GLP-1, which is why it is called a dual agonist, meaning it binds and switches on two receptor types at once. Eli Lilly developed it under the code LY3298176. By receptor count it sits between the two other GLP-1-class peptides Australian Research Peptides lists, semaglutide at one receptor and retatrutide at three.
Its structure is one chain of 39 amino acids that follows the sequence of GIP, a hormone the gut releases. Positions 2 and 13 hold aminoisobutyric acid (Aib), an amino acid the genetic code does not specify, and the last amino acid carries an amide cap, a small chemical end-group. A 20-carbon fatty diacid, meaning a fatty chain with an acid group at each end, is joined through a short linker to the lysine at position 20, which the 2018 discovery paper says lets the molecule bind albumin, a common carrier protein.
In that paper's laboratory binding tests, tirzepatide held the GIP receptor about as tightly as natural GIP and the GLP-1 receptor about five times less tightly than natural GLP-1. Those are measurements made with cells in glassware, not results in any living subject. Australian Research Peptides supplies tirzepatide as freeze-dried reference material for in vitro work, meaning glassware and cell culture.
In Australia, Australian Research Peptides offers tirzepatide to laboratories and researchers as 10 mg, 20 mg and 40 mg vials, and each strength has its own page and stock code. Buyers also search for it as tirz or tirzepatide peptide. Orders are filled from Sydney and posted domestically, so none depends on an overseas shipment clearing customs. The CoA library shows which Tirzepatide strengths, if any, have a published certificate.
BAC water (bacteriostatic water) is also in our range.
Tirzepatide 40 mg specifications, storage and shipping
Compound: Tirzepatide
Quantity: 40 mg
SKU:47263
Presentation: sealed glass vial
Form: Lyophilised Powder
Grade: Research grade
Testing: Independently lab-tested before release
Identity confirmation: Mass spectrometry
Classification: In vitro research purposes only — laboratory reference material
Lyophilised — long term
−20 °C to −80 °C — long-term storage
Lyophilised — short term
2–8 °C — refrigerated, for a few months
Reconstituted
2–8 °C — use within 8–12 weeks
Protect from light and moisture. Handle in accordance with standard laboratory safety practice, including appropriate PPE. This information is provided for laboratory handling only and is not a usage instruction of any kind.
Tirzepatide is independently lab-tested before release. No laboratory report is published for this strength yet. The COA library lists every product and strength, and says which reports are available.
This strength is not in stock today. Stocked lines ordered before 12pm Sydney time on a business day are dispatched the same day with tracked shipping. Standard delivery within Australia typically takes 2–5 business days. See Shipping & Delivery for details, and follow your parcel on the Track Order page.
For in vitro research purposes only. Not for human consumption. Not for animal consumption. Not a drug, food, cosmetic, or dietary supplement. No therapeutic or medical claims are made.
Questions about Tirzepatide 40 mg
This Tirzepatide 40 mg question guide from Australian Research Peptides is specific to this vial: live price and buying details, how it compares with the other two strengths, diluent volume, what the compound is, storage, testing and the legal questions. Start with the quick answers or open the topic you need.
Quick answers
Australian Research Peptides (ARP) sells Tirzepatide 40 mg in Australia under 47263, at $269.99. Standard tracked post and Express Post carry Tirzepatide 40 mg to all states and territories.
The 40 mg Tirzepatide vial is the largest strength Australian Research Peptides lists: forty milligrams of freeze-dried tirzepatide, four times the 10 mg, under a single seal. It carries as much peptide as two 20 mg vials in one piece of glass, so there is one vial to open, one preparation to make and one lot to record.
Tirzepatide 40 mg costs $269.99 a vial (stock code 47263) at Australian Research Peptides, and two 40 mg Tirzepatide vials come to $539.98.
Tirzepatide is a laboratory-made peptide that binds both the GIP and GLP-1 receptors, which is why it is called a dual agonist, and Eli Lilly created it as LY3298176. It is one chain of 39 amino acids following the sequence of GIP, a hormone the gut releases, with a 20-carbon fatty chain attached (Coskun 2018). Australian Research Peptides sells it as freeze-dried powder to laboratories and researchers for in vitro research.
Tirzepatide and retatrutide differ by one receptor: tirzepatide binds GIP and GLP-1, while retatrutide binds GIP, GLP-1 and glucagon, a hormone made in the pancreas. Both are 39-amino-acid chains built on a GIP backbone with a 20-carbon fatty diacid (a fatty chain with an acid group at each end) attached, joined at position 20 on tirzepatide and at position 17 on retatrutide (Li 2024). Australian Research Peptides lists both, and Retatrutide has its own page.
Yes, Tirzepatide from Australian Research Peptides is independently lab-tested before release, and the single-peptide certificates in its library report two results: purity by HPLC, which separates a sample, and identity by mass spectrometry, which weighs the molecule. Identity matters most for tirzepatide, because a batch missing its fatty chain or an Aib position would still look like the same white powder. No matching certificate is currently published for this product and strength.
Exact strength, quantity and listing fit
Four 10 mg Tirzepatide vials cost $519.96; one 40 mg vial is $269.99 — $249.97 less, and three fewer vials to store.
The 40 mg Tirzepatide vial suits a long or multi-arm study that should draw on one vial's material from start to finish, because a single vial means every portion made from it shares the same lot. It also means one preparation history to record instead of several. Work that needs separately sealed portions is better served by the 20 mg vial or the 10 mg.
No, Australian Research Peptides does not list a 60 mg or 30 mg Tirzepatide vial; 40 mg is the largest strength it supplies, alongside the 10 mg and 20 mg. Vial sizes are each seller's own choice, so a 60 mg listed elsewhere does not mean ARP stocks one. An amount above 40 mg on one order is made up from more than one vial, each sealed separately.
The Tirzepatide 10 mg, 20 mg and 40 mg vials hold the same freeze-dried peptide in different amounts, so the number on each is simply the milligrams of tirzepatide sealed inside. The 40 mg vial holds four times as much as the 10 mg vial and twice as much as the 20 mg. Each strength has its own page, stock code and price, and the CoA library shows which strengths have a certificate published.
Per milligram, Tirzepatide 40 mg works out to about $6.75 — $269.99 across 40 mg. The 10 mg Tirzepatide vial works out to about $13.00 a milligram.
The 40 mg Tirzepatide vial is the cheapest per milligram of the three because the fixed cost of a vial, its glass, seal, label and packing, is spread over the most peptide. The per-milligram row on this page works the rate out from the listed price, so it stays right after any price change. The saving comes from fewer containers, not from a different grade or a different compound.
Live price, stock and Australian buying
On Standard tracked post, yes. One Tirzepatide 40 mg vial at $269.99 passes $199 unaided. Free Express Post starts at $299, which this vial misses by $29.01.
$269.99 delivered in Australia. Tirzepatide 40 mg is $269.99, over $199, so 47263 posts free by Standard tracked post. Express Post makes 47263 $286.98.
Two vials of Tirzepatide. At $269.99 each, two 40 mg vials make $539.98 — past $299, so 47263 ships free by Express Post, costing $539.98.
Reconstitution and diluent volume
Australian Research Peptides publishes no fill volume for 47263, so the amount is a decision for the work rather than one the listing sets. 47263 is 40 mg of dry Tirzepatide: what the diluent changes is the solution, never the 40 mg sealed in the glass.
Yes, a 40 mg Tirzepatide vial needs four times the diluent of a 10 mg vial to reach the same concentration, because the liquid scales with the milligrams sealed in the glass. Australian Research Peptides publishes no fill volume for either, since the volume is a choice for the laboratory's method. Using the same volume in both simply gives the 40 mg solution four times the strength.
Product identity and research background
In laboratory binding tests, Tirzepatide binds and switches on two hormone receptors, GIP and GLP-1, where a receptor is the protein on a cell's surface that a hormone locks onto. Coskun 2018 measured binding constants of 0.135 nM (nanomolar, a concentration unit) at the GIP receptor, about the same as natural GIP, and 4.23 nM at the GLP-1 receptor, about five times weaker than natural GLP-1; a lower number means a tighter hold. These are measurements in cells in glassware, not effects in any living subject.
Tirzepatide has 39 amino acids in one continuous chain, built on the sequence of GIP, and two of those positions, 2 and 13, hold aminoisobutyric acid (Aib), an amino acid the genetic code does not specify. The last amino acid carries an amide cap (a small chemical end-group), and the 20-carbon fatty chain on the lysine at position 20 is a side chain, not an extra amino acid in the count (Coskun 2018).
A Tirzepatide vial contains only freeze-dried tirzepatide, a white to off-white powder sealed in glass under a tamper-evident cap, with no liquid, carrier or second peptide added. Its 20-carbon fatty chain is part of the molecule itself, joined to the chain by a chemical bond, so the powder is one compound rather than a blend. The 10 mg, 20 mg or 40 mg on the label is the weight of tirzepatide inside.
Tirzepatide goes by Eli Lilly's development code LY3298176 as well as its generic name, and the 2018 paper that first described it uses the code throughout. Chemistry databases list the molecule as ChEBI:194186. In searches it is shortened to tirz or tirzep, which mean the same compound. It is often grouped with GLP-1 peptides, but it acts at the GIP receptor as well, so it is a dual agonist rather than a GLP-1 copy. Australian Research Peptides lists it by the generic name.
Yes, tirzepatide binds the GLP-1 receptor, but not only that one: it also binds the GIP receptor, so it is classed as a dual GIP/GLP-1 agonist rather than a single-receptor GLP-1 peptide like semaglutide. Its chain is modelled on GIP, not on GLP-1, which is the other way it differs from the GLP-1 copies. Australian Research Peptides lists it in the Metabolic Research range beside semaglutide and retatrutide.
Storage, condition and testing
Tirzepatide should be stored as sealed freeze-dried powder, cold and dry, and Bachem's peptide handling guidance puts lyophilised peptide below -15 °C for long-term storage, with 4 °C in a refrigerator acceptable for short periods. Let a cold vial reach room temperature in a closed, dry container before opening it, because the powder pulls moisture from the air. The 10 mg, 20 mg and 40 mg vials all store the same way.
Yes, a Tirzepatide vial can look almost empty, especially the 10 mg, because ten milligrams of freeze-dried peptide is a thin white film or small disc on the base of the glass. The 20 mg and 40 mg vials hold two and four times as much and show a more obvious cake. Holding the vial against a dark background usually makes the powder visible, and an intact seal is the check that matters.
The certificate that applies to a Tirzepatide vial is the one for its exact strength, because the 10 mg, 20 mg and 40 mg are separate listings, and the CoA library shows which of them has a certificate published. One strength's document never stands in for another's, so a 40 mg vial is matched only against a 40 mg certificate. No matching certificate is currently published for this product and strength.
Legal and pharmacy questions in Australia
Tirzepatide from Australian Research Peptides is sold in Australia only as a reference compound for in vitro laboratory research, not as a medicine, and never for use in a person or an animal. The registered medicine that contains tirzepatide is a separate, finished product dispensed by pharmacies on prescription, and research powder is not a substitute for it. Each buyer is responsible for the rules that govern its own laboratory work.
No, Australian compounding pharmacies can no longer make Tirzepatide, because the TGA says that from 1 October 2024 pharmacists may not compound and supply medicines containing GLP-1 receptor agonists, in any form. The TGA's notice names tirzepatide among the medicines that change covers. Australian Research Peptides does not compound or dispense anything: it supplies research powder to laboratories and researchers for in vitro work.
Yes, the US Food and Drug Administration approved tirzepatide in May 2022, but only as the active ingredient of Eli Lilly's finished prescription medicines, and that approval does not extend to research powder (Drugs@FDA). Each approval covers one manufacturer's product with its own label, set strengths and quality controls. Tirzepatide from Australian Research Peptides is unregistered freeze-dried powder for in vitro laboratory work, not an approved medicine.
